Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ardelyx, Inc. - Common Stock (NQ:ARDX)

5.770 -0.150 (-2.53%)
Streaming Delayed Price Updated: 2:47 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Ardelyx Stock Rises After-Hours On Q4 Beat, Drug Sales Outlook: Retail Gets Big Dose Of Optimism
Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah. 
Via Stocktwits
Ardelyx Tops Estimates as Sales Surge
The biopharma reported strong revenue growth in the fourth quarter thanks to solid performances from both of its approved products, Ibsrela and Xphozah. 
Via The Motley Fool
Palantir Rally Loses Steam, Walmart Outlook Disappoints: What's Driving Markets Thursday?
Stocks tumbled Thursday, with all major indices in the red, one day after the S&P 500 notched another all-time high in Wednesday’s trading session. 
Via Benzinga
Earnings Scheduled For February 20, 2025
 
Via Benzinga
What Analysts Are Saying About Ardelyx Stock
 
Via Benzinga
Beyond The Numbers: 4 Analysts Discuss Ardelyx Stock
 
Via Benzinga
Ardelyx Beats Q3 Sales Estimates, Shares Climb
Ardelyx reported its third-quarter results after Thursday's closing bell. Here's a look at the details from the report: 
Via Benzinga
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025
Conference call scheduled for 8:00 a.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx's Earnings Outlook
 
Via Benzinga
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Responds to District Court Decision Granting Motion to Dismiss
Inclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis patients’ health at risk 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week
From Ardelyx, Inc.
Via GlobeNewswire
ARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ardelyx, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community
Deadline to submit nominations is January 31, 2025 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
From Faruqi & Faruqi, LLP
Via Business Wire
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week
From Ardelyx, Inc.
Via GlobeNewswire
ARDX DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important October 15 Deadline in Securities Class Action – ARDX
From The Rosen Law Firm PA
Via GlobeNewswire
Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From Rosen Law Firm
Via Business Wire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
From Faruqi & Faruqi LLP
Via GlobeNewswire
ARDX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important October 15 Deadline in Securities Class Action – ARDX
From The Rosen Law Firm PA
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.